HLA-associated immune pressure on Gag protein in CRF01_AE-infected individuals and its association with plasma viral load. 2010

Goragoch Gesprasert, and Nuanjun Wichukchinda, and Masahiko Mori, and Teiichiro Shiino, and Wattana Auwanit, and Busarawan Sriwanthana, and Panita Pathipvanich, and Pathom Sawanpanyalert, and Toshiyuki Miura, and Prasert Auewarakul, and Arunee Thitithanyanont, and Koya Ariyoshi
Department of Microbiology, Faculty of Science, Mahidol University, Bangkok, Thailand.

BACKGROUND The human leukocyte antigen (HLA)-restricted cytotoxic T-lymphocyte (CTL) immune response is one of the major factors determining the genetic diversity of human immunodeficiency virus (HIV). There are few population-based analyses of the amino acid variations associated with the host HLA type and their clinical relevance for the Asian population. Here, we identified HLA-associated polymorphisms in the HIV-1 CRF01_AE Gag protein in infected married couples, and examined the consequences of these HLA-selected mutations after transmission to HLA-unmatched recipients. RESULTS One hundred sixteen HIV-1-infected couples were recruited at a government hospital in northern Thailand. The 1.7-kb gag gene was amplified and directly sequenced. We identified 56 associations between amino acid variations in Gag and HLA alleles. Of those amino acid variations, 35 (62.5%) were located within or adjacent to regions reported to be HIV-specific CTL epitopes restricted by the relevant HLA. Interestingly, a significant number of HLA-associated amino acid variations appear to be unique to the CRF01_AE-infected Thai population. Variations in the capsid protein (p24) had the strongest associations with the viral load and CD4 cell count. The mutation and reversion rates after transmission to a host with a different HLA environment varied considerably. The p24 T242N variant escape from B57/58 CTL had a significant impact on the HIV-1 viral load of CRF01_AE-infected patients. CONCLUSIONS HLA-associated amino acid mutations and the CTL selection pressures on the p24 antigen appear to have the most significant impact on HIV replication in a CRF01_AE-infected Asian population. HLA-associated mutations with a low reversion rate accumulated as a footprint in this Thai population. The novel HLA-associated mutations identified in this study encourage us to acquire more extensive information about the viral dynamics of HLA-associated amino acid polymorphisms in a given population as effective CTL vaccine targets.

UI MeSH Term Description Entries
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D006680 HLA Antigens Antigens determined by leukocyte loci found on chromosome 6, the major histocompatibility loci in humans. They are polypeptides or glycoproteins found on most nucleated cells and platelets, determine tissue types for transplantation, and are associated with certain diseases. Human Leukocyte Antigen,Human Leukocyte Antigens,Leukocyte Antigens,HL-A Antigens,Antigen, Human Leukocyte,Antigens, HL-A,Antigens, HLA,Antigens, Human Leukocyte,Antigens, Leukocyte,HL A Antigens,Leukocyte Antigen, Human,Leukocyte Antigens, Human
D000483 Alleles Variant forms of the same gene, occupying the same locus on homologous CHROMOSOMES, and governing the variants in production of the same gene product. Allelomorphs,Allele,Allelomorph
D001483 Base Sequence The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence. DNA Sequence,Nucleotide Sequence,RNA Sequence,DNA Sequences,Base Sequences,Nucleotide Sequences,RNA Sequences,Sequence, Base,Sequence, DNA,Sequence, Nucleotide,Sequence, RNA,Sequences, Base,Sequences, DNA,Sequences, Nucleotide,Sequences, RNA
D013602 T-Lymphocytes, Cytotoxic Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2. Cell-Mediated Lympholytic Cells,Cytotoxic T Cells,Cytotoxic T Lymphocyte,Cytotoxic T-Lymphocytes,TC1 Cell,TC1 Cells,TC2 Cell,TC2 Cells,Cell Mediated Lympholytic Cells,Cell, Cell-Mediated Lympholytic,Cell, TC1,Cell, TC2,Cell-Mediated Lympholytic Cell,Cytotoxic T Cell,Cytotoxic T Lymphocytes,Cytotoxic T-Lymphocyte,Lymphocyte, Cytotoxic T,Lympholytic Cell, Cell-Mediated,Lympholytic Cells, Cell-Mediated,T Cell, Cytotoxic,T Lymphocyte, Cytotoxic,T Lymphocytes, Cytotoxic,T-Lymphocyte, Cytotoxic
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D015683 Gene Products, gag Proteins coded by the retroviral gag gene. The products are usually synthesized as protein precursors or POLYPROTEINS, which are then cleaved by viral proteases to yield the final products. Many of the final products are associated with the nucleoprotein core of the virion. gag is short for group-specific antigen. Viral gag Proteins,gag Antigen,gag Gene Product,gag Gene Products,gag Polyproteins,gag Protein,gag Viral Proteins,Gene Product, gag,Retroviral Antigen gag Protein,gag Antigens,gag Gene Related Protein,gag Polyprotein,Antigen, gag,Antigens, gag,Polyprotein, gag,Polyproteins, gag,Protein, gag,Proteins, Viral gag,Proteins, gag Viral,Viral Proteins, gag,gag Proteins, Viral
D016133 Polymerase Chain Reaction In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships. Anchored PCR,Inverse PCR,Nested PCR,PCR,Anchored Polymerase Chain Reaction,Inverse Polymerase Chain Reaction,Nested Polymerase Chain Reaction,PCR, Anchored,PCR, Inverse,PCR, Nested,Polymerase Chain Reactions,Reaction, Polymerase Chain,Reactions, Polymerase Chain
D017931 DNA Primers Short sequences (generally about 10 base pairs) of DNA that are complementary to sequences of messenger RNA and allow reverse transcriptases to start copying the adjacent sequences of mRNA. Primers are used extensively in genetic and molecular biology techniques. DNA Primer,Oligodeoxyribonucleotide Primer,Oligodeoxyribonucleotide Primers,Oligonucleotide Primer,Oligonucleotide Primers,Primer, DNA,Primer, Oligodeoxyribonucleotide,Primer, Oligonucleotide,Primers, DNA,Primers, Oligodeoxyribonucleotide,Primers, Oligonucleotide
D019562 Viral Load The quantity of measurable virus in a body fluid. Change in viral load, measured in plasma, is sometimes used as a SURROGATE MARKER in disease progression. Viral Burden,Virus Titer,Burden, Viral,Load, Viral,Titer, Virus

Related Publications

Goragoch Gesprasert, and Nuanjun Wichukchinda, and Masahiko Mori, and Teiichiro Shiino, and Wattana Auwanit, and Busarawan Sriwanthana, and Panita Pathipvanich, and Pathom Sawanpanyalert, and Toshiyuki Miura, and Prasert Auewarakul, and Arunee Thitithanyanont, and Koya Ariyoshi
July 1999, AIDS (London, England),
Goragoch Gesprasert, and Nuanjun Wichukchinda, and Masahiko Mori, and Teiichiro Shiino, and Wattana Auwanit, and Busarawan Sriwanthana, and Panita Pathipvanich, and Pathom Sawanpanyalert, and Toshiyuki Miura, and Prasert Auewarakul, and Arunee Thitithanyanont, and Koya Ariyoshi
January 2011, PloS one,
Goragoch Gesprasert, and Nuanjun Wichukchinda, and Masahiko Mori, and Teiichiro Shiino, and Wattana Auwanit, and Busarawan Sriwanthana, and Panita Pathipvanich, and Pathom Sawanpanyalert, and Toshiyuki Miura, and Prasert Auewarakul, and Arunee Thitithanyanont, and Koya Ariyoshi
January 2010, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases,
Goragoch Gesprasert, and Nuanjun Wichukchinda, and Masahiko Mori, and Teiichiro Shiino, and Wattana Auwanit, and Busarawan Sriwanthana, and Panita Pathipvanich, and Pathom Sawanpanyalert, and Toshiyuki Miura, and Prasert Auewarakul, and Arunee Thitithanyanont, and Koya Ariyoshi
January 2017, Current HIV research,
Goragoch Gesprasert, and Nuanjun Wichukchinda, and Masahiko Mori, and Teiichiro Shiino, and Wattana Auwanit, and Busarawan Sriwanthana, and Panita Pathipvanich, and Pathom Sawanpanyalert, and Toshiyuki Miura, and Prasert Auewarakul, and Arunee Thitithanyanont, and Koya Ariyoshi
October 2016, Human immunology,
Goragoch Gesprasert, and Nuanjun Wichukchinda, and Masahiko Mori, and Teiichiro Shiino, and Wattana Auwanit, and Busarawan Sriwanthana, and Panita Pathipvanich, and Pathom Sawanpanyalert, and Toshiyuki Miura, and Prasert Auewarakul, and Arunee Thitithanyanont, and Koya Ariyoshi
February 1998, Immunology letters,
Goragoch Gesprasert, and Nuanjun Wichukchinda, and Masahiko Mori, and Teiichiro Shiino, and Wattana Auwanit, and Busarawan Sriwanthana, and Panita Pathipvanich, and Pathom Sawanpanyalert, and Toshiyuki Miura, and Prasert Auewarakul, and Arunee Thitithanyanont, and Koya Ariyoshi
May 2008, The Journal of experimental medicine,
Goragoch Gesprasert, and Nuanjun Wichukchinda, and Masahiko Mori, and Teiichiro Shiino, and Wattana Auwanit, and Busarawan Sriwanthana, and Panita Pathipvanich, and Pathom Sawanpanyalert, and Toshiyuki Miura, and Prasert Auewarakul, and Arunee Thitithanyanont, and Koya Ariyoshi
April 2008, PloS one,
Goragoch Gesprasert, and Nuanjun Wichukchinda, and Masahiko Mori, and Teiichiro Shiino, and Wattana Auwanit, and Busarawan Sriwanthana, and Panita Pathipvanich, and Pathom Sawanpanyalert, and Toshiyuki Miura, and Prasert Auewarakul, and Arunee Thitithanyanont, and Koya Ariyoshi
July 2013, Journal of acquired immune deficiency syndromes (1999),
Goragoch Gesprasert, and Nuanjun Wichukchinda, and Masahiko Mori, and Teiichiro Shiino, and Wattana Auwanit, and Busarawan Sriwanthana, and Panita Pathipvanich, and Pathom Sawanpanyalert, and Toshiyuki Miura, and Prasert Auewarakul, and Arunee Thitithanyanont, and Koya Ariyoshi
November 1993, AIDS (London, England),
Copied contents to your clipboard!